Accelerating Cell Line Development From DNA To Master Cell Bank

The growing use of therapeutic strategies such as bispecific and monoclonal antibodies (mAbs), recombinant proteins, and vaccines is increasing demand for cell line development (CLD) at a double-digit compound annual growth rate. However, CLD is a complicated process presenting multiple manufacturing hurdles, and partnering with a CDMO is an effective strategy to ensure these complex products are manufactured with speed and quality.

Leveraging an accelerated timeline to develop the master cell bank (MCB) not only decreases wait times and ultimately delivers a drug substance in fewer months, but the minimized handling decreases the risk of contamination and lowers the chance of batch failure. Read more about the steps necessary to accelerate timelines and decrease wait times to a MCB.